• Masako To, Yasuo To, Hirokazu Yamada, Chuhei Ogawa, Mamoru Otomo, Naohito Suzuki, and Yasuyuki Sano.
• Department of Allergy and Respiratory Medicine, Doai Memorial Hospital, 2-1-11 Yokoami Sumida-ku, Tokyo 130-8587.
• Intern. Med. 2004 Aug 1;43(8):674-8.

ObjectiveThe aim of the present study was to evaluate the influence of inhaled corticosteroids (ICS) on community-acquired pneumonia (CAP) in patients with asthma.Patients And MethodsAll asthmatic patients who required hospitalization for CAP from the beginning of 1989 through December 2001 were enrolled in this retrospective study. Patients who used oral corticosteroids daily were excluded. Patients were divided into two groups based on whether or not they used ICS, and we analyzed clinical characteristics of the pneumonia. Sixty-two patients (28 males, 34 females; mean age, 54.5 years) were enrolled in this study. Thirty-seven of 62 patients used ICS, with the mean dosage being 777.9 microg/day.ResultsWe found no significant differences between the two groups with regard to mean age, serum albumin level, duration of asthma, pulmonary function and frequency of intravenous infusion of corticosteroids in the outpatient department. There were no significant differences in body temperature, white blood cell count, and CRP value upon admission between the two groups. Differences were not significant in the period of resolution of the pneumonia or in the frequency of pathogens identified between the two groups.ConclusionICS therapy appears to have no influence on CAP in patients with asthma. We recommend that ICS should be continued to control asthma with adequate antibiotic therapy when asthmatic patients have CAP.

18 keywords...

hide…